Aptamer Group to host technical development update webinar

Aptamer Group plc (LON:APTA), the leading developer of next-generation synthetic binders delivering innovation to the life science industry, has announced that Dr David Bunka, Chief Scientific Officer, will host a webinar to provide an update on the Company’s progress within its technical development programmes.

The webinar will be broadcast on Thursday, 14 August 2025, at 6:00 pm (BST) and will offer a detailed review of the latest data and technical developments, building on insights shared through recent regulatory announcements.

The webinar is open to shareholders and other interested parties who can register for the event by using the following link: https://www.turnerpope.com/register/

Share on:

You might also enjoy reading Aptamer expands odour control collaboration with Unilever

Written by: Amilia Stone

Find more news, interviews, share price & company profile here for:

Latest Company News

Aptamer advances enzyme modulation projects and expands pharma collaboration

Aptamer Group announced progress on its Optimer® enzyme modulation projects, including a 10-year non-exclusive licensing deal forecast to cover around 15% of annual overheads and further agreements under discussion with global enzyme distributors.

Aptamer secures contract Eetension with top 5 pharma partner

Aptamer has extended its collaboration with a top 5 global pharmaceutical company to advance Optimer® binders into a fully functional ELISA assay. The agreement builds on the successful completion of the initial binder development phase, with Aptamer retaining IP ownership to support future commercialisation opportunities.

Aptamer Group to host technical development update webinar

Aptamer will hold a webinar on 14 August 2025 at 6:00 pm BST, led by Chief Scientific Officer Dr David Bunka, to present the latest data and progress across its technical development programmes.

Aptamer Group reports 41% revenue growth and new licensing deals

Aptamer Group posted unaudited revenue of £1.20 million for the year ended 30 June 2025, up 41% from the previous year. The company secured two new royalty agreements and advanced multiple licensing discussions, supported by a strengthened cash position following a £1.83 million fundraise.

Aptamer Group extends Unilever collaboration for deodorant Optimers

Aptamer Group has secured additional paid work from Unilever under their existing collaboration, advancing Optimers as deodorant actives with expanded stability testing ahead of on‑person trials.

Aptamer Group raises £2.0 million in share placing

Aptamer has raised £2.0 million (before expenses) by placing 666,666,666 new ordinary shares at 0.3 p each, representing 25.1 per cent of its enlarged issued share capital. The proceeds will accelerate commercialisation of the Optimer® platform, support in-house manufacturing, launch new biomarker services and develop AI-driven aptamer discovery.